This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. MENS, CALT, ZYME, SBTX, MBX, NLTX, AVTE, CYBN, BIOA, and VIRIShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Jyong Biotech (MENS), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Aerovate Therapeutics (AVTE), Cybin (CYBN), BioAge Labs (BIOA), and Virios Therapeutics (VIRI). Aquinox Pharmaceuticals vs. Its Competitors Jyong Biotech Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Neoleukin Therapeutics Aerovate Therapeutics Cybin BioAge Labs Virios Therapeutics Aquinox Pharmaceuticals (NASDAQ:AQXP) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Which has preferable earnings and valuation, AQXP or MENS? Jyong Biotech has lower revenue, but higher earnings than Aquinox Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M20.20-$31.58MN/AN/AJyong BiotechN/AN/AN/AN/AN/A Does the media prefer AQXP or MENS? In the previous week, Aquinox Pharmaceuticals' average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score. Company Overall Sentiment Aquinox Pharmaceuticals Neutral Jyong Biotech Neutral Is AQXP or MENS more profitable? Jyong Biotech's return on equity of 0.00% beat Aquinox Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% Jyong Biotech N/A N/A N/A Do insiders & institutionals hold more shares of AQXP or MENS? 71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAquinox Pharmaceuticals beats Jyong Biotech on 3 of the 5 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$504.93M$784.96M$5.59B$9.53BDividend YieldN/A4.84%4.71%4.14%P/E RatioN/A1.3028.8923.88Price / Sales20.2025.05448.2598.82Price / CashN/A19.5635.6858.35Price / Book6.946.478.175.60Net Income-$31.58M-$4.35M$3.25B$265.26M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$21.45-1.2%N/A-41.0%$504.93M$25M0.008MENSJyong BiotechN/A$26.00+10.8%N/AN/A$1.98BN/A0.0031Gap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks3.061 of 5 stars$12.42-1.4%$21.00+69.1%+25.4%$866.44M$93.38M-8.29460Upcoming EarningsSBTXSilverback TherapeuticsN/A$17.38+1.2%N/A+86.5%$626.69MN/A-7.1883High Trading VolumeMBXMBX Biosciences2.7973 of 5 stars$12.20-2.7%$37.63+208.4%N/A$405.87MN/A0.0036News CoverageAnalyst ForecastGap UpNLTXNeoleukin TherapeuticsN/A$21.72-0.3%N/A-45.1%$204.13MN/A-6.9890AVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-88.0%$199.71MN/A-2.3020News CoverageUpcoming EarningsHigh Trading VolumeCYBNCybin2.8678 of 5 stars$7.56-1.6%$85.00+1,024.3%N/A$177.75MN/A-1.7250Positive NewsBIOABioAge LabsN/A$4.45+0.7%N/AN/A$159.53MN/A0.00N/AVIRIVirios TherapeuticsN/A$4.86+0.2%$5.00+2.9%+2,501.7%$93.59MN/A-18.005 Related Companies and Tools Related Companies MENS Competitors CALT Competitors ZYME Competitors SBTX Competitors MBX Competitors NLTX Competitors AVTE Competitors CYBN Competitors BIOA Competitors VIRI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 8/6/2025 by MarketBeat.com Staff From Our Partners[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQXP Stock Alerts